KURA ONCOLOGY REPORTS DURABLE CLINICAL ACTIVITY OF DARLIFARNIB PLUS CABOZANTINIB IN CABOZANTINIB-NAÏVE CLEAR CELL RENAL CELL CARCINOMA PATIENTS AT KCRS 2026

Reuters · 2d ago

Please log in to view news